Juan Buades

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

David Adams, Alejandra González‐Duarte, William O’Riordan et al. · New England Journal of Medicine · 2018 · 2.9K citations · Full text

Life Sciences, Molecular Biology, Pharmacology +14

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study

Ole B. Suhr, Teresa Coelho, Juan Buades et al. · Orphanet Journal of Rare Diseases · 2015 · 322 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis

Teresa Coelho, David Adams, Isabel Conceição et al. · Orphanet Journal of Rare Diseases · 2020 · 52 citations · Full text

Medicine, Neurology, Pharmacotherapy +13

Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis

Joel N. Buxbaum, Thomas H. Brannagan, Juan Buades et al. · Amyloid · 2019 · 32 citations

Medicine, Ophthalmology, Surgery +12

Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease

W Bakker, Hiddo J.L. Heerspink, Stefan P. Berger et al. · Nephrology Dialysis Transplantation · 2025 · 19 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13